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We thank Professor Cohen for his reply and his interesting points regarding the possible role 
of inadequate folinic acid rescue in contributing to neurotoxic side-effects of methotrexate. We 
can confirm that the patient reported in our article [1] had not received any previous exposure 
to any systemic methotrexate (oral or intravenous) even at low dose. In addition, the other 
published article on this possible interaction with nitrous oxide [2] reported a patient 
developing symptoms early during induction therapy on a protocol with a standard 3-drug 
induction (vincristine, asparaginase and corticosteroids). Therefore, concomitant systemic 
methotrexate appears not to be a contributing factor in either of these reported cases.  
As pointed out by Prof Cohen the recent article by Krull et al [3] indicates, for the first time in 
acute lymphoblastic leukaemia (ALL), a direct association between methotrexate plasma levels 
(area under the curve) and adverse long-term neurocognitive outcomes.  The role of folinic 
acid rescue in prevention of neurotoxic side effects remains speculative [4,5]  and has never 
been tested in a randomised trial. In addition, the impact of over-rescue on leukaemic relapse 
is still uncertain [6,7] and differences in scheduling and concomitant chemotherapy as well as 
individual pharmacogenomics are all likely to play a part. 
It is worth noting that nitrous oxide irreversibly inactivates vitamin B12 - a co-factor for 
methionine synthase- rather than directly interfering with Methotrexate induced inhibition of 
dihydrofolate reductase [8]. Since methionine synthase activity is required for homocysteine 
to methionine conversion,  it may be that, in the presence of low/inactive B12, the efficacy of 
folinic acid rescue in reducing neurotoxic symptoms related to high homocysteine [9] and/or 
low methionine is more limited.  In other words, even in the presence of adequate folinic acid 
rescue, the conversion of homocysteine to methionine may still be impaired due to low 
methionine synthase activity. However, to our knowledge this has never been tested 
experimentally. 
In summary, further studies are clearly needed to investigate the optimal dosing of both 
methotrexate and folinic acid rescue in order to balance efficacy and toxicity. Yet, we still 
believe that the most effective way of reducing this potential drug interaction is to limit 
exposure to nitrous oxide, especially as a number of safe non-toxic alternative anaesthetic 
agents are in routine use.   
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